ArticlePloS one2026
A minimally invasive lab protocol for fibroblasts isolation from 1-mm skin punch biopsies in pediatric patients.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Skin biopsies provide a valuable source of culturable cells for a broad range of clinical and biomedical research applications. However, conventional methods for establishing primary cell cultures typically require relatively large tissue specimens obtained through invasive procedures that involve intradermal anesthesia, suturing, and subsequent wound care. These factors are of particular concern when working with pediatric populations. To address these limitations, we developed a simplified protocol that reduces patient discomfort by minimizing the punch biopsy diameter to as little as 1 mm. Despite the markedly smaller sample size, this method consistently enables the successful establishment of primary fibroblast cultures, with no complications reported to date. This streamlined approach is compatible with basic cell culture facilities and provides a reliable source of fibroblasts for downstream applications. Overall, this protocol represents a meaningful advancement in both pediatric research and clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.